- Home
- OFLX vs IMAB Comparison
OFLX vs IMAB Comparison
Compare OFLX & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFLX
- IMAB
- Stock Information
- Founded
- OFLX 1975
- IMAB 2014
- Country
- OFLX United States
- IMAB United States
- Employees
- OFLX N/A
- IMAB N/A
- Industry
- OFLX Industrial Specialties
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- OFLX Industrials
- IMAB Health Care
- Exchange
- OFLX Nasdaq
- IMAB Nasdaq
- Market Cap
- OFLX 366.4M
- IMAB 384.6M
- IPO Year
- OFLX 2005
- IMAB 2020
- Fundamental
- Price
- OFLX $34.31
- IMAB $3.62
- Analyst Decision
- OFLX
- IMAB Strong Buy
- Analyst Count
- OFLX 0
- IMAB 5
- Target Price
- OFLX N/A
- IMAB $6.80
- AVG Volume (30 Days)
- OFLX 18.1K
- IMAB 1.8M
- Earning Date
- OFLX 10-29-2025
- IMAB 11-02-2025
- Dividend Yield
- OFLX 3.91%
- IMAB N/A
- EPS Growth
- OFLX N/A
- IMAB N/A
- EPS
- OFLX 1.69
- IMAB N/A
- Revenue
- OFLX $100,700,000.00
- IMAB N/A
- Revenue This Year
- OFLX N/A
- IMAB N/A
- Revenue Next Year
- OFLX N/A
- IMAB N/A
- P/E Ratio
- OFLX $20.00
- IMAB N/A
- Revenue Growth
- OFLX N/A
- IMAB N/A
- 52 Week Low
- OFLX $28.12
- IMAB $0.60
- 52 Week High
- OFLX $57.81
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- OFLX 50.57
- IMAB 44.27
- Support Level
- OFLX $33.32
- IMAB $3.20
- Resistance Level
- OFLX $35.26
- IMAB $4.64
- Average True Range (ATR)
- OFLX 1.20
- IMAB 0.43
- MACD
- OFLX -0.14
- IMAB -0.17
- Stochastic Oscillator
- OFLX 31.73
- IMAB 20.49
About OFLX Omega Flex Inc.
Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States. The company derives revenues from the manufacture and sale of flexible metal hose and accessories.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).